<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Effect of antidepressants on suicide risk in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Effect of antidepressants on suicide risk in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Effect of antidepressants on suicide risk in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Scott Moreland, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Liza Bonin, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There is concern that selective serotonin reuptake inhibitors (SSRIs) and other antidepressants may increase the risk of suicidal ideation and behavior in children, adolescents, and adults younger than 25 years [<a href="#rid1">1-4</a>]. In early 2004, the US Food and Drug Administration (FDA) in the United States asked manufacturers of a number of antidepressants to make labeling changes to include a warning about a possible increased risk of suicidal ideation or behavior, particularly at the initiation of therapy or at the time of dose changes [<a href="#rid5">5</a>]. After further analysis, in October 2004, the FDA directed manufacturers of all antidepressants (including tricyclic antidepressants and monoamine oxidase inhibitors) to include a warning stating that antidepressants may increase the risk of suicidal ideation and behavior in children and adolescents [<a href="#rid6">6</a>].</p><p>Establishing the causal association is difficult because of the clear associations between severe depression and suicide and between severe depression and the need for antidepressant therapy. Because suicide is uncommon, it also is difficult to demonstrate the negative, which is that antidepressants do not cause suicide. Risk factors for suicidal behavior in children and adolescents are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1229.html" rel="external">"Suicidal behavior in children and adolescents: Epidemiology and risk factors", section on 'Psychiatric disorder'</a>.)</p><p>This topic discusses the evidence regarding antidepressants and the risk of suicide in children and adolescents. The use of antidepressants in adolescent depression is discussed separately, as is the association between antidepressants and suicide risk in adults. (See  <a class="medical medical_review" href="/z/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication"</a> and  <a class="medical medical_review" href="/z/d/html/14672.html" rel="external">"Effect of antidepressants on suicide risk in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EVIDENCE OF ASSOCIATION</span></p><p class="headingAnchor" id="H3"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Evidence for and against an association between antidepressant therapy and suicidal thoughts and/or behaviors in children, adolescents, and young adults comes from randomized trials [<a href="#rid7">7-11</a>], observational studies [<a href="#rid12">12-14</a>], and population-based studies comparing the rates of suicide and antidepressant use over time [<a href="#rid15">15-19</a>]. Each of these study designs has limitations in demonstrating a causal association [<a href="#rid20">20,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Suicide is rare in randomized, controlled trials of antidepressants. Thus, individual trials typically lack the power to detect a relationship between antidepressants and suicidal ideation or behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Observational studies can more easily detect rare events such as suicide. However, causality is difficult to establish because of the association between severe depression and the use of antidepressants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Population-based studies have examined rates of antidepressant use and suicide over time. These studies have generally found lower rates of suicide with increasing rates of antidepressant use [<a href="#rid15">15-19</a>]. Accordingly, the consensus has been that increases in prescribing likely yield lower rates of suicide. However, rare antidepressant-induced suicides could be masked by secular trends [<a href="#rid22">22</a>]. In addition, the use of newer antidepressants (eg, selective serotonin reuptake inhibitors) may be a marker for better overall quality of health care [<a href="#rid19">19</a>]. Thus, it is not clear that increased rates of antidepressant prescribing are the cause of decreasing rates of suicide [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Randomized trials</span><span class="headingEndMark"> — </span>Randomized trials of antidepressants in children and adolescents were not designed primarily to determine whether these antidepressants increase suicidal behavior [<a href="#rid23">23</a>]. Most of the trials excluded subjects with suicidal ideation and did not have enough power to detect rare adverse events such as suicide deaths. Suicidal ideation and behavior were not methodically assessed as prespecified outcomes in earlier studies; rather, suicidal ideation and behavior were spontaneously reported as adverse events and were not uniformly defined [<a href="#rid10">10</a>]. More recent studies have systematically evaluated suicidal ideation and behavior in pediatric antidepressant trials, prompted partly by the US Food and Drug Administration’s (FDA) concern of a lack of standardized language to define, monitor, and clinically assess suicidal behavior [<a href="#rid24">24-26</a>]. One study (n = 334 patients) found that suicidal ideation and behavior were detected less often by spontaneous reporting, compared with systematic assessment (9 versus 21 percent of patients) [<a href="#rid25">25</a>].</p><p>In addition, patients in randomized trials who are assigned to treatment with active drug often have more side effects, which may have led to increased contact with study personnel and a greater opportunity to report suicidal ideation and behavior (ascertainment bias) [<a href="#rid27">27</a>]. Most of the reported suicidal events were suicidal thoughts, rather than suicidal behavior.</p><p>Systematic reviews of randomized trials, subject to the limitations described above, have yielded different conclusions about the association between antidepressants and increased risk of suicidal ideation and behavior, as illustrated in the two subsections below. In many instances, the reviews conducted meta-analyses that pooled results from trials in patients with different disorders, such as unipolar major depression, anxiety disorders, and obsessive-compulsive disorder.</p><p class="headingAnchor" id="H2597502872"><span class="h3">Evidence of an increased risk</span></p><p class="bulletIndent1"><span class="glyph">●</span>The FDA convened an advisory panel to reexamine analyses regarding suicidal thoughts and behaviors and antidepressants in children and adolescents. The advisory panel's combined analysis of 24 short-term (4 to 16 weeks), placebo-controlled trials of nine antidepressant medications in more than 4400 children and adolescents being treated for unipolar major depression and other psychiatric disorders yielded the following results [<a href="#rid11">11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Seventy-eight patients (2 percent) experienced adverse events representing suicidal ideation or behavior, collectively termed suicidality; adverse events were reports made by the research clinician if a patient or parent spontaneously shared thoughts about suicidality [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the adverse events that were reported, patients on antidepressant medication had an increased risk of suicidality during the first few months of treatment compared with those on placebo (4 versus 2 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 17 trials, standardized forms were used to ask each patient about suicidality at each visit. The data revealed that medication neither increased the suicidality that was present before treatment, nor induced suicidality in patients who were not thinking about suicide at the start of the study. Over the course of treatment, all studies combined showed a slight reduction in suicidality.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No completed suicides occurred during any of the trials.</p><p></p><p class="bulletIndent1">The FDA advisory panel concluded that there was a small increased risk of suicidal thoughts or behavior in children taking antidepressants compared with placebo (risk ratio 2.0, 95% CI 1.3-3.0) [<a href="#rid11">11</a>]. The risk appeared to be greatest in the first few weeks after initiating therapy [<a href="#rid11">11,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 27 trials (n &gt;5300 youth) found a small increased risk of suicidal ideation or behavior in patients taking antidepressants than placebo (0.7 percent; 95% CI 0.1-1.3) [<a href="#rid30">30</a>]. The number needed to harm was 143, meaning one additional episode of suicidal ideation or behavior occurred with antidepressants for every 143 youth taking antidepressants and every 143 youth taking placebo. The investigators concluded that the benefits of antidepressants far outweighed the risks of suicidal ideation/behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 17 trials (n &gt;3200 children and adolescents) compared antidepressants (selective serotonin reuptake inhibitors [SSRIs], <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>, or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) with placebo and found that suicidal ideation or behavior occurred in more patients who received antidepressants (risk ratio 1.58, 95% CI 1.02-2.45) [<a href="#rid31">31</a>]. The authors estimated that this translated to an increase in suicidal events of approximately 1.5 percent, in contrast to an increase in remission of 6.8 percent; thus, the rate of remission was 4.5 times greater than the rate of suicidal ideation and behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A network meta-analysis included 34 randomized trials that evaluated 14 different antidepressants in pediatric patients with acute major depression (n &gt;5000); the study used direct comparisons between two drugs or between a drug and placebo, as well as indirect comparisons of the drugs through their relative effect with a common comparator (typically placebo) [<a href="#rid32">32</a>]. The study found that the risk of suicidal ideation or behavior was greater with <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> than placebo, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>.</p><p></p><p class="headingAnchor" id="H3595260867"><span class="h3">Evidence of no increased risk</span></p><p class="bulletIndent1"><span class="glyph">●</span>The American College of Neuropsychopharmacology Task Force report on SSRIs and Suicidal Behavior in Youth reviewed 15 trials (n &gt;2000) regarding the safety and effectiveness of five antidepressants (<a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) [<a href="#rid10">10</a>]. The rate of suicidal ideation and behavior was similar between those treated with antidepressants and placebo, and there were no completed suicides.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analysis of FDA summary reports of randomized trials of nine second-generation antidepressants found 77 suicides among 48,277 patients [<a href="#rid7">7</a>]. Rates of suicide based on patient exposure years were similar among those receiving an SSRI (0.59 percent [95% CI 0.31-0.87 percent]), a different antidepressant (a combination of the newer antidepressants being studied and the older antidepressants used in the active control arms of the studies) (0.76 percent [95% CI 0.49-1.03 percent]), and placebo (0.45 percent [95% CI 0.01-0.89 percent]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of patient-level data from four randomized trials (708 children and adolescents with unipolar major depression) found that the risk of suicidal thoughts and behavior was comparable for <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> and placebo [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review identified seven randomized trials published since 2007 that compared antidepressants with placebo for unipolar major depression (total number of youth not reported); in each trial, the rate of suicidal ideation/behavior with active drug and placebo was comparable [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Observational studies</span><span class="headingEndMark"> — </span>Observational studies have yielded inconsistent results regarding the association of antidepressants with suicidal behavior. Differences in results may be due at least partially to study methods, such as adjusting the analyses for potential confounding factors:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of eight observational studies (n &gt;200,000 patients) found that exposure to selective serotonin reuptake inhibitors (SSRIs) in adolescents with moderate or severe depression was associated with an increased risk for attempted or completed suicide (OR 1.9, CI 1.5-2.4) [<a href="#rid14">14</a>]. However, adolescents who received treatment with SSRIs may have been more severely depressed and at greater risk of suicide than those who did not receive SSRIs (confounding by indication).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent retrospective study used an administrative claims database to examine the use of antidepressants and the number of suicide attempts that occurred before and after the FDA issued its warnings about a possible increased risk of suicidal ideation and behavior due to antidepressants [<a href="#rid34">34</a>]. The dataset included a cohort of children and adolescents aged 10 to 17 years (n &gt;1 million), and the analyses used psychotropic drug poisonings as a proxy for suicide attempts. The study found that in the second year (2006) after the warnings, use of antidepressants declined by 31 percent, whereas psychotropic drug poisonings increased by 22 percent. It is worth noting that psychotropic poisonings may reflect substance abuse rather than suicidality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another subsequent study used administrative databases to identify youth ages 5 to 17 years with new episodes of depression (n &gt;200,000), who were followed for up to 180 days [<a href="#rid27">27</a>]. The analyses compared the frequency of self-harm (suicide attempts and self-inflicted injury) in patients who were either treated or not treated with antidepressants, and included adjustments for potential confounding due to patient characteristics that change over time (eg, demographics, prior self-harm, comorbid conditions, and psychiatric hospitalization) and can affect the probability of receiving an antidepressant and the outcome of treatment. Although the initial unadjusted analyses found that antidepressant treatment was associated with an increased risk of self-harm, the adjusted analyses did not.</p><p></p><p>Observational studies suggest that in children and adolescents, the risk of suicide attempts associated with selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors appears to be similar across different medications [<a href="#rid35">35</a>]. As an example, a retrospective study using an insurance claims database and medical records identified more than 38,000 youth who were treated with <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, including 419 patients with medically treated suicide attempts [<a href="#rid36">36</a>]. After adjusting for the propensity to receive a particular antidepressant as well as factors such as age, mental health diagnoses, and use of psychotropic medications, the analyses showed that the rate of suicide attempts for users of fluoxetine was comparable to the rate for each of the other antidepressants. However, the risk of suicide attempts was elevated in patients treated with multiple antidepressants concurrently, compared with patients who were treated with fluoxetine alone (relative risk 1.7, 95% CI 1.1-2.6). This elevated risk may reflect increased severity of depression rather than a drug effect.</p><p>In addition, relatively high starting doses of antidepressants prescribed for children and adolescents appear to be associated with suicidal behavior. An observational study used an insurance claims database of depressed patients aged 10 to 24 years (n &gt;39,000), and compared the incidence of suicide attempts in patients who started SSRIs at modal (eg, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> 20 mg or <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> 50 mg per day) or higher than modal doses [<a href="#rid37">37</a>]. The analyses included propensity score matching to balance the two groups with regard to observed potential confounders (eg, depression severity and previous self-harm). The risk of deliberate self-harm was two-fold greater in patients who initiated treatment at the higher dose (hazard ratio 2.2, 95% CI 1.6-3.0). This corresponded to approximately one additional suicide attempt for every 130 patients who started treatment with each regimen. Despite propensity score matching, it is possible that patients started at higher doses were at greater risk for suicidal behavior due to a history of treatment nonresponse or treatment response only at higher doses [<a href="#rid38">38</a>]. In addition, the study did not address the risk of suicidal behavior associated with dose escalation conducted in line with clinical guidelines (eg, fluoxetine 10 mg for one week, then fluoxetine 20 mg for 3 weeks, and then increase only in patients who do not respond).</p><p class="headingAnchor" id="H8"><span class="h1">RECOMMENDATIONS OF VARIOUS GROUPS</span><span class="headingEndMark"> — </span>In response to concerns about the increased risk of suicidality with antidepressant therapy, various regulatory and clinical groups have taken a closer look at the data, and based upon their conclusions, made recommendations regarding the use of antidepressants in children and adolescents.</p><p class="headingAnchor" id="H9"><span class="h2">FDA black box warning</span><span class="headingEndMark"> — </span>In 2004, the US Food and Drug Administration (FDA) directed manufacturers of antidepressants  (<a class="graphic graphic_table graphicRef80584" href="/z/d/graphic/80584.html" rel="external">table 1</a>) to revise the labeling of their products to include a boxed warning and expanded warning statements about the risks of suicidality in children and adolescents being treated with these drugs  (<a class="graphic graphic_table graphicRef54498" href="/z/d/graphic/54498.html" rel="external">table 2</a>) [<a href="#rid6">6,39</a>]. In May 2007, the FDA extended the warning to include adults younger than 25 years [<a href="#rid21">21,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/14672.html" rel="external">"Effect of antidepressants on suicide risk in adults"</a>.)</p><p>The FDA also updated the medication guide and product labeling to remind health care providers that depression and certain other serious psychiatric disorders are themselves the most important causes of suicide [<a href="#rid41">41</a>].</p><p>The warning applies to any and all use of antidepressant drugs in children and adolescents. The warning requires any clinician prescribing antidepressant medication to clearly warn the patient and his/her family about the potential risks associated with these medications. In addition, the FDA has determined that all patients receiving these medications should be given a Patient Medication Guide (MedGuide) to advise them of the risk and precautions that can be taken  (<a class="graphic graphic_table graphicRef77780" href="/z/d/graphic/77780.html" rel="external">table 3</a>) [<a href="#rid42">42</a>]. MedGuides are intended to be distributed by the pharmacist with each new prescription or refill of antidepressant medication.</p><p class="headingAnchor" id="H10"><span class="h2">Other groups</span><span class="headingEndMark"> — </span>Other regulatory and clinical groups have come to differing conclusions regarding the safety and efficacy of antidepressants in children, as illustrated below.</p><p class="bulletIndent1"><span class="glyph">●</span>The United Kingdom's Medicines and Healthcare Products Regulatory Agency found only <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> to have a favorable risk-benefit profile [<a href="#rid43">43</a>]. It recommends against the use of <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>, and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> for the treatment of unipolar major depression in children [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American College of Neuropsychopharmacology (ACNP) Task Force on SSRIs and Suicidal Behavior in Youth concluded that, because depression is one of the largest risk factors for suicide, diagnosis and treatment of depression in children and adolescents require urgent attention [<a href="#rid44">44</a>]. The Task Force found that among the antidepressants, only <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> has demonstrated strong statistical evidence of efficacy. The Task Force also concluded that, based on the FDA meta-analysis, selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are associated with a small increase in the risk of suicidality. However, other lines of evidence (eg, population-based studies comparing the rates of suicide and antidepressant use over time [<a href="#rid15">15-19</a>], toxicology studies of completed suicides [<a href="#rid45">45,46</a>], and cohort studies [<a href="#rid47">47,48</a>]) indicated a possible beneficial effect of antidepressant therapy on the risk of suicide. The Task Force recommends the continued use of fluoxetine as an effective and readily available treatment for major depression in children and adolescents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Academy of Child and Adolescent Psychiatry (AACAP) supported the conclusions of the ACNP Task Force. The AACAP Work Group recommended that its members continue to treat depression with all of the effective means available. Effective treatment, based on available research, includes treatment with an antidepressant only, an antidepressant with CBT, or CBT alone. The AACAP supports a combined treatment approach as the most efficacious [<a href="#rid28">28,49</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> has the most evidence of efficacy and is considered the first-line medication [<a href="#rid28">28</a>]. However, because 30 to 40 percent of patients may not respond to fluoxetine and others will be unable to tolerate it because of side effects, alternative medications are often necessary; other SSRIs are most appropriate. In the Treatment of Resistant Depression in Adolescents randomized trial, patients who had not responded to initial treatment with an SSRI showed comparable reduction in symptoms when treated with fluoxetine, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid50">50</a>]. The treating clinician, in conjunction with the patient and family, must determine the best treatment option for the individual patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Society for Adolescent Medicine strongly supports the appropriate use of antidepressant medications in the treatment for adolescents with depression [<a href="#rid51">51</a>]. When using such medications, the risk of suicidality must be balanced with the clinical need.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">MONITORING FOR SUICIDALITY</span><span class="headingEndMark"> — </span>Patients who are treated with antidepressants must be closely monitored by the clinician and family. Details of monitoring, including frequency and parameters, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88735.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: General principles", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">IMPACT OF THE FDA ADVISORY</span><span class="headingEndMark"> — </span>Integrated claims data from national managed care plans in the United States were used to evaluate patterns of diagnosis and treatment of depression in children and adolescents before and after the US Food and Drug Administration (FDA) advisory on risk of suicidality with selective serotonin reuptake inhibitors (SSRIs) in 2004 [<a href="#rid34">34,41,52-54</a>]. Between 1999 and 2004, the rates of diagnosis of new episodes of pediatric depression and of treatment with SSRIs were increasing. After the FDA advisory, there was a reversal in both of these trends, without evidence of a significant increase in other treatment modalities. In addition, care and treatment of children and adolescents with depression shifted from generalists to psychiatrists.</p><p>The aforementioned studies did not evaluate the possible underlying causes of the shifts in diagnosis of depression and prescribing of antidepressants for children and adolescents. One possibility is that the original increase in depression rates and use of antidepressants in children reflected over-diagnosis and misuse of medication. If this is correct, then the decrease after the FDA warnings is an appropriate outcome. Alternatively, current practice could reflect a substantial problem with under-diagnosis and undertreatment of depression.</p><p>What is clear is that since the FDA warnings, general practitioners are diagnosing less pediatric depression and prescribing fewer antidepressants to children and adolescents [<a href="#rid41">41,52,53</a>]. While psychiatrists are treating slightly more youth depression, it is not enough to compensate for the observed decline in primary care. The observed rates of diagnosis after the FDA advisory (0.3 to 0.5 percent) are substantially lower than previously published incidences of child (0.4 to 2.5 percent) and adolescent depression (0.4 to 8.3 percent) [<a href="#rid52">52</a>]. It is still too soon to know the impact and meaning of these trends on the treatment and prognosis of depression in children and adolescents. Some studies show that five years from the FDA Advisory, the initial decline in SSRI prescriptions for children and adolescents has reversed, whereas another study shows the decline is ongoing. Continued monitoring and studies are needed [<a href="#rid34">34,55,56</a>].</p><p>According to the United States Centers for Disease Control and Prevention (CDC), 1985 suicides occurred among children and adolescents aged 10 through 19 years in 2004, compared with 1737 in 2003 [<a href="#rid57">57,58</a>]. This was the first increase in the suicide rate in this age group in more than ten years. Similarly, in the Netherlands, the suicide rate in children and adolescents increased by 49 percent between 2003 and 2005; during the same time period, SSRI prescriptions for children and adolescents decreased by 22 percent [<a href="#rid59">59</a>].</p><p>Similar results were found in a 2008 Canadian study which examined data 9 years before and 2 years after Health Canada’s regulatory warning on prescribing antidepressants to children and adolescents (which occurred in June 2003, 4 months before the FDA’s October warning). Suicide deaths in children and adolescents increased significantly by 25 percent, corresponding to a significant decrease in antidepressant prescriptions of 14 percent [<a href="#rid60">60</a>]. In addition, changes were found in treatment that was not directly targeted by the warning: antidepressant prescriptions for young adults (18 to 24 years) decreased significantly, as did follow up visits for depression for children, adolescents, and young adults.</p><p>The black box warning was intended to bring attention to and close monitoring of antidepressants in children and adolescents, not to decrease the amount of prescriptions and/or treatment for depression. The apparent unexpected effect of the regulatory actions on clinician's prescribing practices is a cause for significant concern, particularly in the context of evidence that antidepressant treatment in children and adolescents is beneficial [<a href="#rid61">61</a>].</p><p>The debate concerning risk for suicidality with antidepressants compared to the risk of suicide in untreated or undertreated depression has significant consequences. Beyond working to clarify the nature of the relationship between suicide and antidepressants, systemic monitoring of the consequences of regulatory warnings is an ongoing need. Approximately two-thirds of children and adolescents with a mental disorder do not receive adequate treatment [<a href="#rid62">62</a>]. Anything that significantly interferes with access to care should be a cause for concern.</p><p class="headingAnchor" id="H1754239608"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4867.html" rel="external">"Patient education: Depression in children and adolescents (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4870.html" rel="external">"Patient education: Depression treatment options for children and adolescents (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>There appears to be a slightly increased risk of suicidal thoughts and behaviors (but not completed suicide) among a small group of children and adolescents who are treated with antidepressant medications compared with placebo. However, the evidence is inadequate to conclusively establish this association. (See <a class="local">'Evidence of association'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The US Food and Drug Administration (FDA) has directed manufacturers of antidepressants  (<a class="graphic graphic_table graphicRef80584" href="/z/d/graphic/80584.html" rel="external">table 1</a>) to include a boxed warning label regarding the increased risk of suicidality  (<a class="graphic graphic_table graphicRef54498" href="/z/d/graphic/54498.html" rel="external">table 2</a>), thus requiring the prescribing clinician to discuss the warning with the patient and family. In addition, all patients receiving antidepressants should be given a Patient Medication Guide (MedGuide) to advise them of the risk and precautions that can be taken  (<a class="graphic graphic_table graphicRef77780" href="/z/d/graphic/77780.html" rel="external">table 3</a>). (See <a class="local">'FDA black box warning'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When considering the use of antidepressants in children and adolescents, the risk of antidepressant-related suicidality must be weighed against the benefits of treatment and the long-term risk of suicide in untreated depression. When considering this balance, the consensus among most mental health specialists is that the benefits of antidepressant therapy outweigh the risks. The ratio of response to suicidal events is approximately 11:1, and for remission to suicidal events is 4.5:1 (See <a class="local">'Other groups'</a> above and <a class="local">'Randomized trials'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children and adolescents who are treated with antidepressants should start on low doses and be closely monitored by clinicians and families for increasing suicidal thoughts or behaviors. (See  <a class="medical medical_review" href="/z/d/html/88735.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: General principles", section on 'Monitoring'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72:71.</a></li><li><a class="nounderline abstract_t">Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363:1341.</a></li><li><a class="nounderline abstract_t">Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328:879.</a></li><li><a class="nounderline abstract_t">Kafali N, Progovac A, Hou SS, Cook BL. Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning. Psychiatr Serv 2018; 69:389.</a></li><li class="breakAll">US FDA. Public Health Advisory. Worsening depression and suicidality in patients being treated with antidepressant medications. March 22, 2004. www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm (Accessed on May 29, 2006).</li><li class="breakAll">US FDA. Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. October 15, 2004. www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm (Accessed on May 29, 2006).</li><li><a class="nounderline abstract_t">Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790.</a></li><li><a class="nounderline abstract_t">Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303:685.</a></li><li><a class="nounderline abstract_t">March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.</a></li><li class="breakAll">American College of Neuropsychopharmacology. Preliminary report of the Task Force on SSRIs and Suicidal Behavior in Youth. January 21, 2004. www.acnp.org (Accessed on September 13, 2007).</li><li><a class="nounderline abstract_t">Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63:332.</a></li><li><a class="nounderline abstract_t">Fux M, Taub M, Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993; 88:235.</a></li><li><a class="nounderline abstract_t">Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Arch Gen Psychiatry 2006; 63:865.</a></li><li><a class="nounderline abstract_t">Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009; 180:291.</a></li><li><a class="nounderline abstract_t">Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003; 326:1008.</a></li><li><a class="nounderline abstract_t">Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60:978.</a></li><li><a class="nounderline abstract_t">Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001; 10:525.</a></li><li><a class="nounderline abstract_t">Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand 1997; 96:94.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165.</a></li><li><a class="nounderline abstract_t">Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med 2004; 350:1489.</a></li><li><a class="nounderline abstract_t">Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356:2343.</a></li><li><a class="nounderline abstract_t">Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004; 329:34.</a></li><li><a class="nounderline abstract_t">Rappaport N, Prince JB, Bostic JQ, Association of Medical School Pediatric Department Chairs, Inc. Lost in the black box: juvenile depression, suicide, and the FDA's black box. J Pediatr 2005; 147:719.</a></li><li><a class="nounderline abstract_t">Ignaszewski MJ, Waslick B. Update on Randomized Placebo-Controlled Trials in the Past Decade for Treatment of Major Depressive Disorder in Child and Adolescent Patients: A Systematic Review. J Child Adolesc Psychopharmacol 2018; 28:668.</a></li><li><a class="nounderline abstract_t">Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166:418.</a></li><li class="breakAll">US Food and Drug Administration. FDA statement regarding Background Information on the Suicidality Classification Project. March 22, 2004 https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm161679.htm (Accessed on December 06, 2018).</li><li><a class="nounderline abstract_t">Gibbons RD, Coca Perraillon M, Hur K, et al. Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents. Pharmacoepidemiol Drug Saf 2015; 24:208.</a></li><li class="breakAll">American Academy of Child and Adolescent Psychiatry. Supplementary talking points for child and adolescent psychiatrists regarding the FDA black box warning on the use of antidepressants for pediatric patients. November 2004. www.aacap.org/announcements/psychiatricmeds.htm (Accessed on June 29, 2006).</li><li><a class="nounderline abstract_t">Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292:338.</a></li><li><a class="nounderline abstract_t">Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683.</a></li><li><a class="nounderline abstract_t">Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD004851.</a></li><li><a class="nounderline abstract_t">Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016; 388:881.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:580.</a></li><li><a class="nounderline abstract_t">Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ 2014; 348:g3596.</a></li><li><a class="nounderline abstract_t">Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 2010; 125:876.</a></li><li><a class="nounderline abstract_t">Cooper WO, Callahan ST, Shintani A, et al. Antidepressants and suicide attempts in children. Pediatrics 2014; 133:204.</a></li><li><a class="nounderline abstract_t">Miller M, Swanson SA, Azrael D, et al. Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med 2014; 174:899.</a></li><li><a class="nounderline abstract_t">Brent DA, Gibbons R. Initial dose of antidepressant and suicidal behavior in youth: start low, go slow. JAMA Intern Med 2014; 174:909.</a></li><li class="breakAll">Labeling change request letter for antidepressant medications. www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm (Accessed on June 29, 2006).</li><li class="breakAll">US Food and Drug Administration. Center for Drug Evaluation and Research. Antidepressant use in children, adolescents, and adults. www.fda.gov/cder/drug/antidepressants/default.htm (Accessed on May 02, 2007).</li><li class="breakAll">FDA Revised Talk Paper: FDA Proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. May 2, 2007. www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html (Accessed on July 26, 2008).</li><li class="breakAll">FDA proposed medication guide: about using antidepressants in children for teenagers. www.fda.gov/cder/drug/antidepressants/SSRIMedicationGuide.htm (Accessed on June 29, 2006).</li><li class="breakAll">Selective serotonin reuptake inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. www.mhra.gov.uk (Accessed on June 29, 2006).</li><li><a class="nounderline abstract_t">Mann JJ, Emslie G, Baldessarini RJ, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31:473.</a></li><li><a class="nounderline abstract_t">Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005; 111:286.</a></li><li><a class="nounderline abstract_t">Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004; 65:915.</a></li><li><a class="nounderline abstract_t">Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163:41.</a></li><li><a class="nounderline abstract_t">Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18:1119.</a></li><li><a class="nounderline abstract_t">Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.</a></li><li><a class="nounderline abstract_t">Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.</a></li><li><a class="nounderline abstract_t">Lock J, Walker LR, Rickert VI, et al. Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine. J Adolesc Health 2005; 36:92.</a></li><li><a class="nounderline abstract_t">Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164:884.</a></li><li><a class="nounderline abstract_t">Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64:466.</a></li><li><a class="nounderline abstract_t">Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66:633.</a></li><li><a class="nounderline abstract_t">Mittal M, Harrison DL, Miller MJ, Brahm NC. National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning. Res Social Adm Pharm 2014; 10:781.</a></li><li><a class="nounderline abstract_t">Clarke G, Dickerson J, Gullion CM, DeBar LL. Trends in youth antidepressant dispensing and refill limits, 2000 through 2009. J Child Adolesc Psychopharmacol 2012; 22:11.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years--United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56:905.</a></li><li><a class="nounderline abstract_t">Hamilton BE, Miniño AM, Martin JA, et al. Annual summary of vital statistics: 2005. Pediatrics 2007; 119:345.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164:1356.</a></li><li><a class="nounderline abstract_t">Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178:1005.</a></li><li><a class="nounderline abstract_t">Mosholder AD, Pamer CA. Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. J Child Adolesc Psychopharmacol 2006; 16:33.</a></li><li class="breakAll">National Mental Health Information Center, Center for Mental Health Services. Children and Mental Health Fast Facts, 2000. mentalhealth.samhsa.gov/publications/allpubs/fastfact5/default.asp (Accessed on July 25, 2008).</li></ol></div><div id="topicVersionRevision">Topic 1225 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601224" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110490" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073072" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Efficacy and safety of antidepressants for children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241433" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241433" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241433" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668373" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15315995" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15315995" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520440" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Suicidality in pediatric patients treated with antidepressant drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256637" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894062" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188627" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742921" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557142" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relationship between antidepressant medication treatment and suicide in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11828835" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antidepressant medication and suicide in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9272192" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699293" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The relationship between antidepressant medication use and rate of suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071123" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antidepressant medications in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485726" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Expanding the black box - depression, antidepressants, and the risk of suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231620" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antidepressants and suicide: what is the balance of benefit and harm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16356415" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lost in the black box: juvenile depression, suicide, and the FDA's black box.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30063169" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Update on Randomized Placebo-Controlled Trials in the Past Decade for Treatment of Major Depressive Disorder in Child and Adolescent Patients: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223438" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223438" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25263479" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25263479" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265848" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antidepressants and the risk of suicidal behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440145" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152227" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Newer generation antidepressants for depressive disorders in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27289172" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309973" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942789" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385637" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394688" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antidepressants and suicide attempts in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24782035" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antidepressant dose, age, and the risk of deliberate self-harm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781493" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Initial dose of antidepressant and suicidal behavior in youth: start low, go slow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781493" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Initial dose of antidepressant and suicidal behavior in youth: start low, go slow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781493" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Initial dose of antidepressant and suicidal behavior in youth: start low, go slow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781493" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Initial dose of antidepressant and suicidal behavior in youth: start low, go slow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781493" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Initial dose of antidepressant and suicidal behavior in youth: start low, go slow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781493" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Initial dose of antidepressant and suicidal behavior in youth: start low, go slow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319919" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : ACNP Task Force report on SSRIs and suicidal behavior in youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740464" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291679" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390887" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Suicide risk during antidepressant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581382" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18049300" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18314433" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15702497" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541047" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404123" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487628" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Persisting decline in depression treatment after FDA warnings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355381" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22251026" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Trends in youth antidepressant dispensing and refill limits, 2000 through 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17805220" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Suicide trends among youths and young adults aged 10-24 years--United States, 1990-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272625" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Annual summary of vital statistics: 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728420" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390943" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553527" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
